Diligence memo · auto-generated · as of July 2, 2026
Titan Pharmaceuticals Inc
Titan Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Titan Pharmaceuticals Inc operates in Pharmaceuticals, based in SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Titan Pharmaceuticals Inc has raised $15M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.7M on 2021-01-20.
Most recent recorded round closed around 2022-02-04.
Valuation (modeled)modeled
Provath models Titan Pharmaceuticals Inc at approximately $23M (range $1.7M–$87M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.71× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era. Within the normal band (71% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 4.4 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 6.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 62% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 29% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.